Abstract
In Saudi Arabia AFP considered the main serum marker for diagnostic Hepatocellular carcinoma (HCC), due to the continuous detection of HCC in Saudi Arabia, using new biomarkers for early surveillance are essential to control in prevalence of HCC. The present study depend on compare the significant between serum and mRNA Glypican-3 (GPC-3) as newly identified diagnostic and prognostic biomarkers for HCC between study cases. And combined sensitivity of AFP and GPC-3. Three hundred study cases, divided into: 250 blood samples were 145 samples from HCC , 105 samples from chronic liver cirrhosis (CLC) and 50 normal controls were investigated for serum GPC-3 (sGPC-3) by Sandwich ELISA. Glypican-3 mRNA from whole blood cells was detected by quantitative RT-PCR. The comparison between two techniques was by sensitivity and specificity. The results of sGPC-3 showed higher significant in HCC group than CLC and normal controls (p<0.001). sGPC-3 sensitivity was 95% and specificity was 100%, while in GPC-3 mRNA were 100% and 94% respectively. The combination of sensitivity between AFP and sGPC-3 was 80% and 95% respectively. The data demonstrated that, can depend on sGPC-3 and Glypican-3 mRNA as tumor biomarkers for detection and surveillance of Hepatocellular carcinoma in Saudi patients. The sensitivity of Reverse Transcriptase-PCR is high accurate (100%) than estimating sGPC-3 by ELISA (95%).
Highlights
In Saudi Arabia alpha fetoprotein (AFP) considered the main serum marker for diagnostic Hepatocellular carcinoma (HCC), due to the continuous detection of HCC in Saudi Arabia, using new biomarkers for early surveillance are essential to control in prevalence of HCC
The highest results of serum GPC-3 (sGPC-3) were detected in HCC with Hepatitis B virus (HBV) and HCV positive compared to HBV and HCV negative patients.It was 96% (120/125), 90% (18/20) in positive and negative hepatitis virus HCC patients respectively
In somereports recorded that the sensitivity for diagnosis of Hepatocellular carcinoma approximately 25%-60%, and its specificity is low and AFP was estimated in patients with chronic liver cirrhosis (CLC) range between 11%-47% and 15%-58% in non -cirrhosischronic hepatitis patients[2].In addition, 30% HCC patients present with normal AFP
Summary
In Saudi Arabia AFP considered the main serum marker for diagnostic Hepatocellular carcinoma (HCC), due to the continuous detection of HCC in Saudi Arabia, using new biomarkers for early surveillance are essential to control in prevalence of HCC. The present study depend oncompare the significant between serum and mRNA Glypican-3 (GPC-3) as newly identified diagnostic and prognostic biomarkers for HCC between study cases.And combined sensitivity of AFP and GPC-3. Three hundred study cases, divided into: 250 blood samples were 145 samples from HCC , 105 samples from chronic liver cirrhosis (CLC) and 50normal controls were investigated for serum GPC-3 (sGPC-3) bySandwich ELISA. SGPC-3 sensitivity was 95% and specificity was100%, while inGPC-3 mRNA were 100% and 94% respectively. The data demonstrated that, can depend on sGPC-3 and Glypican-3 mRNA as tumor biomarkers fordetection and surveillance of Hepatocellular carcinoma in Saudi patients. On other hand AFP is significant in casestumor size is >3 to 5, But it was in significant in HCC with small size < 25, 6.depend on AFP as the famous biomarker for detection and follow-up of HCC isn’t accurate and for early surveillance of HCCneeded to a new diagnostic markers[7]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.